The stock's fall snapped a three-day winning streak.

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares soared to an all-time high this week, reaching a peak of $24.44. According to InvestingPro data, the company maintains an "EXCELLENT" financial ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 484,666 shares of the biopharmaceutical company’s stock ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...

Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for ...

This was the stock's second consecutive day of losses.